Amneal Pharmaceuticals Inc. presented at the Jefferies Global Healthcare Conference 2025, highlighting a new chapter of growth as a global biopharmaceutical company. The company reported significant diversification and expansion of its portfolio from 2019 to 2024, driving sustainable long-term growth through execution, innovation, and business development. Key areas of focus include expanding in high-growth areas such as GLP-1/Peptides, advancing the biosimilars pipeline, and growing specialty assets like CREXONT® for Parkinson's Disease and Brekiya® for migraine and cluster headache. Financial projections for 2025 indicate an increase in net revenues to $3.0 - $3.1 billion and adjusted EBITDA to $650M - $675M, with a notable reduction in net leverage. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。